Altmetrics
Downloads
360
Views
231
Comments
0
A peer-reviewed article of this preprint also exists.
supplementary.xlsx (71.50KB )
This version is not peer-reviewed
Submitted:
20 May 2024
Posted:
21 May 2024
You are already at the latest version
Selection criteria | Inclusion criteria | Exclusion criteria |
---|---|---|
Year of publication | All articles published from inception of the databases to 2023 | Articles published outside this period. |
Type of publication | Peer review articles, grey literature and specific unpublished reports from stakeholders involved in vaccine administration and policy in Nigeria | Preprints, Thesis and dissertations and other publications that have not been peer reviewed. |
Language | English | All other languages |
Issue | Determinants of childhood vaccine uptake | Drivers and facilitators of COVID-19, influenza vaccines and other vaccines not included in the NPHDA routine immunization schedule as at October 2023 |
Sample | Under 2 children eligible for routine immunization in accordance to the NPHCDA recommendations, their caregivers including their parents and healthcare workers administering vaccine and providing necessary logistics and administrative responsibilities. |
Phenomenon of interest | Routine vaccination recommended by the NPHCDA |
Design | This includes primary studies employing exploratory, observational, or experimental study designs |
Evaluation | Behaviours towards vaccination |
Research type | This is mainly qualitative or mixed methods |
Characteristics | Number of studies (%), n=110 | References |
---|---|---|
Publication period | ||
Before 1990 | 1 (0.9%) | [1] |
Between 1990 and 2010 | 5 (4.5%) | [2,3,4,5,6] |
After 2010 | 104 (94.5%) | [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109] |
Geographical Regions | ||
Multi-states | 11 (10.0 %) | [35,46,67,74,77,83,91,98,108] |
National | 26 (23.6 %) | [2,5,15,19,20,22,26,34,40,41,42,46,50,56,59,60,65,71,75,76,78,84,88,90,94,107] |
North-Central | 4 (3.6 %) | [13,61,62,97] |
North-East | 9(8.2 %) | [16,34,54,58,86,92,93,95] |
North-West | 17 (15.5 %) | [8,9,11,18,29,31,32,39,45,47,55,57,100,102,105,106,109] |
South-East | 12 (10.9 %) | [10,25,28,63,64,68,69,70,89,103] |
South-South | 10 (17.3 %) | [3,12,23,24,48,51,53,80,96,104] |
South-West | 21 (19.1 %) | [1,4,6,7,14,17,27,30,33,37,38,43,44,49,52,72,73,82,87,99,101] |
Research approach | ||
Mixed Method | 44 (40.0 %) | [1,2,5,12,13,16,19,20,21,26,31,34,35,38,39,40,42,43,44,46,50,52,53,54,56,71,72,73,74,75,76,78,83,84,85,86,90,92,94,95,101,107,109] |
Qualitative | 61 (55.5 %) | [1,3,4,6,7,8,9,10,14,15,17,18,22,23,24,25,27,28,29,30,32,33,34,35,37,41,45,46,47,48,49,51,55,57,58,60,61,62,63,64,65,67,68,69,70,77,80,81,82,87,89,91,92,93,96,97,98,99,100,102,103,104,105,106] |
Quantitative | 5 (4.5 %) | [35,41,47,60,65] |
Data collection methods | ||
Combination of methods | 12 (10.9 %) | [9,35,43,73,74,83,101] |
Analysis of secondary data | 33 (30.0 %) | [2,5,18,19,20,34,36,40,41,42,50,53,54,56,59,60,65,71,75,76,84,86,88,90,92,94,96,107,109,110,111] |
Focus Groups | 7 (6.4 %) | [12,17,21,57,62,80,102] |
Interviews | 18 (16.4 %) | [1,3,4,6,15,17,35,48,51,61,68,97,98,103,105,106,108] |
Observation | 6 (5.5 %) | [14,22,27,37,58,91] |
Questionnaire and household surveys | 34 (306 %) | [8,10,11,13,23,24,25,28,30,31,32,33,34,38,39,45,47,49,52,55,63,64,67,69,70,77,81,82,85,89,99,104] [87,100] |
Vaccines assessed | ||
Routine immunization | 89 (80.9 %) | [1,3,4,5,6,7,8,9,10,12,13,14,15,17,19,21,23,24,26,29,30,31,32,34,35,37,38,39,40,41,42,43,45,46,47,48,49,50,51,52,53,55,56,57,58,60,62,63,64,67,68,71,72,73,74,75,76,77,79,80,81,82,83,84,85,86,87,88,89,90,93,94,95,96,97,99,100,101,102,104,105,106,107,110,111] |
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine | 2 (1.8 %) | [2,33] |
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine; Polio Vaccine | 1 (0.9 %) | [33] |
Hepatitis B Vaccine | 3 (2.7 %) | [16,69,70] |
Measles, Mumps, and Rubella (MMR) Vaccine | 5 (4.5 %) | [28,61,92,108] |
Polio Vaccine | 10 (9.1 %) | [11,20,22,54,65,91,98,103,109,112] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated